Medical devices, healthcare technology and the business of care
510(k) clearance · K252712

STIMPOD NMS460 Nerve Stimulator

Algiamed Technologies USA, Inc. · Decision date May 28, 2026

FDA DECISIONK252712

What did the FDA decide?

FDA records K252712 as a 510(k) premarket notification, with a decision dated May 28, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
May 28, 2026

FDA source record

Regulatory record facts

Identifier
K252712
Regulatory pathway
510(k) premarket notification
Product code
GZJ
Decision code
SESE
Decision date
May 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, Nerve, Transcutaneous, For Pain Relief.

Product code
GZJ
FDA device class
2

FDA decision timeline

  1. K252712 received

    Application receipt date recorded by FDA.

  2. K252712 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code GZJ

Product / regulatory recordCompanyPathwayDecision dateSource
SUBLIMED510(k) clearanceJan 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Algiamed Technologies USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Lake Mary, FL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records